PACS Group (NYSE:PACS) Director Mark Hancock Sells 4,280 Shares of Company Stock

PACS Group, Inc. (NYSE:PACS) Director Mark Hancock sold 4,280 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $50.02, for a total value of $214,085.60. Following the sale, the director directly owned 53,505,580 shares of the company’s stock, valued at approximately $2,676,349,111.60. This represents a 0.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hancock also recently made the following trade(s):

• On Wednesday, October 28th, Mark Hancock sold 9,024 shares of PACS Group stock. The stock was sold at an average price of $50.10, for a total value of $452,102.40.
• On Tuesday, September 15th, Mark Hancock sold 155,682 shares of PACS Group stock. The stock was sold at an average price of $42.47, for a total value of $6,611,814.54.
• On Monday, September 14th, Mark Hancock sold 144,318 shares of PACS Group stock. The stock was sold at an average price of $44.57, for a total transaction of $6,432,253.26.

PACS Group Stock Performance

Shares of PACS opened at $47.76 on Friday. The company has a 50-day moving average of $44.21 and a two-hundred day moving average of $39.79. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of 27.77, a PEG ratio of 1.55 and a beta of -0.08. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.91 and a quick ratio of 0.91. PACS Group, Inc. has a one year low of $10.31 and a one year high of $50.38.

PACS Group (NYSE:PACS) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.09. PACS Group had a net margin of 4.85% and a return on equity of 29.55%. The business had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.41 billion. On average, equities research analysts expect that PACS Group, Inc. will post 2.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. UBS Group boosted their target price on shares of PACS Group from $57.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded PACS Group from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Zacks Research cut PACS Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 9th. Oppenheimer lifted their price target on PACS Group from $48.00 to $57.00 and gave the company an “outperform” rating in a report on Monday, August 10th. Finally, Wall Street Zen lowered PACS Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.80.

PACS Group News Summary

Here are the key news stories impacting PACS Group this week:

• Neutral Sentiment: CEO Jason Murray, Director Mark Hancock, and Chief Accounting Officer Michelle Lewis collectively sold approximately 33,935 shares for about $1.70 million at prices near $50 per share. However, the transactions were executed under pre-arranged 10b5-1 plans, and the executives continue to hold substantial positions. The sales therefore appear more consistent with scheduled diversification or liquidity needs than a clear indication of weakening confidence. Mark Hancock insider-trading filing Jason Murray insider-trading filing Michelle Lewis insider-trading filing
• Negative Sentiment: A shareholder-focused law firm issued an alert encouraging PACS investors to contact the Shareholders Foundation regarding a potential lawsuit. The notice provides no confirmed allegations or details about the case in the supplied report, so the immediate financial impact is uncertain, but litigation-related headlines can create additional volatility and concern around the stock. PACS shareholder lawsuit alert

Institutional Investors Weigh In On PACS Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PACS. Dimensional Fund Advisors LP boosted its stake in shares of PACS Group by 370.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 780,159 shares of the company’s stock valued at $25,051,000 after buying an additional 614,250 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of PACS Group during the 2nd quarter worth about $8,196,000. Principal Financial Group Inc. purchased a new stake in shares of PACS Group during the 1st quarter worth about $3,171,000. Arrowstreet Capital Limited Partnership raised its stake in shares of PACS Group by 44.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 288,718 shares of the company’s stock worth $9,274,000 after purchasing an additional 89,067 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of PACS Group during the 3rd quarter valued at about $1,920,000.

PACS Group Company Profile

PACS Group, Inc is a U.S.-based healthcare services company that owns and operates post-acute care facilities. Its platform focuses primarily on skilled nursing and transitional care, serving patients who require rehabilitation, recovery support, long-term care, and other services following hospitalization or acute medical treatment.

The company’s operations also include assisted living, independent living, and behavioral health services in select locations. Through its facilities and related healthcare capabilities, PACS Group provides services such as nursing care, physical and occupational therapy, speech therapy, medical treatment, and support for patients with complex or extended care needs.

Founded in 2013 and headquartered in Farmington, Utah, PACS Group serves communities across multiple U.S.